Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer

World Journal of Gastroenterology

Volumn 21, Issue 43, 2015, Pages 12234-12248

  Fujita, Ken Ichi ^a   Kubota, Yutaro ^a   Ishida, Hiroo ^a   Sasaki, Yasutsuna ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Dosing; Irinotecan; Metastatic colorectal cancer; Personalized chemotherapy; Severe renal failure; Survival advantage

Indexed keywords

FIRTECAN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ALLELE; BODY SIZE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DOUBLE STRANDED DNA BREAK; DRUG METABOLISM; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SINGLE STRANDED DNA BREAK; SURVIVAL TIME; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOTRANSFORMATION; COLORECTAL NEOPLASMS; DOSE CALCULATION; GENETICS; GENOTYPE; METASTASIS; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG DOSAGE CALCULATIONS; GENOTYPE; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84948993611     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i43.12234     Document Type: Review

References (115)

1. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76: 952-962 [PMID: 9328159].
2. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamPTothec in, a novel water-soluble derivative of camPTothecin, against murine tumors. Cancer Res 1987; 47: 5944-5947 [PMID: 3664496].
3. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618 [PMID: 25337750 DOI: 10.1056/NEJMoa1403108].
4. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16: 1068-1074 [PMID: 9508192].
5. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807 [PMID: 11559717].
6. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995; 86: 406-413 [PMID: 7775263].
7. GuPTa E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725 [PMID: 8033091].
8. GuPTa E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15: 1502-1510 [PMID: 9193346].
9. Guillemette C, Lévesque É, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther 2014; 96: 324-339 [PMID: 24922307 DOI: 10.1038/clPT.2014.126].
10. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926 [PMID: 11156391].
11. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244 [PMID: 16636344 DOI: 10.1200/JCO.2005.03.0239].
12. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388 [PMID: 15007088 DOI: 10.1200/JCO.2004.07.173].
13. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1∗6 and ∗28. Pharmacogenet Genomics 2007; 17: 497-504 [PMID: 17558305 DOI: 10.1097/FPC.0b013e328014341f].
14. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-2194 [PMID: 11489791].
15. Sparreboom A, Fujita K, Zamboni WC. Topoisomerase I-Targeting Drugs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2010: 342-355.
16. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 1997; 57: 1934-1938 [PMID: 9157988].
17. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 1998; 58: 5137-5143 [PMID: 9823324].
18. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Ishikawa T, Tanabe S, Kohno S. Transport of 7-ethyl-10-hydroxycamPTothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288: 827-832 [PMID: 11688982 DOI: 10.1006/bbrc.2001.5850].
19. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uPTake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamPTothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33: 434-439 [PMID: 15608127 DOI: 10.1124/dmd.104.001909].
20. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, Mano N. Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008; 260: 163-169 [PMID: 18082941 DOI: 10.1016/j.canlet.2007.10.040].
21. Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y. Direct inhibition and down-regulation by uremic plasma components of hepatic uPTake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 2014; 31: 204-215 [PMID: 23921491 DOI: 10.1007/s11095-013-1153-x].
22. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camPTothecin. Cancer Res 1988; 48: 1722-1726 [PMID: 2832051].
23. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camPTothecin. Cancer Res 1989; 49: 5077-5082 [PMID: 2548710].
24. Beretta GL, Cossa G, Gatti L, Zunino F, Perego P. Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camPTothecinbased treatment. Curr Med Chem 2010; 17: 1500-1508 [PMID: 20166932].
25. Hu Z, Ma H, Lu D, Zhou J, Chen Y, Xu L, Zhu J, Huo X, Qian J, Wei Q, Shen H. A promoter polymorphism (-77T& gt; C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics 2005; 15: 457-463 [PMID: 15970793].
26. Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camPTothecin resistance. Cancer Res 2002; 62: 459-465 [PMID: 11809696].
27. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22: 7296-7304 [PMID: 14576839 DOI: 10.1038/sj.onc.1206935].
28. Han JY, Lee GK, Yoo SY, Yoon SJ, Cho EY, Kim HT, Lee JS. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics J 2010; 10: 86-93 [PMID: 19859084 DOI: 10.1038/tpj.2009.46].
29. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in secondline therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807-814 [PMID: 12610178].
30. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518 [PMID: 11230497].
31. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418 [PMID: 9807987 DOI: 10.1016/S0140-6736(98)02309-5].
32. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412 [PMID: 9807986 DOI: 10.1016/S0140-6736(98)03085-2].
33. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914 [PMID: 11006366].
34. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047 [PMID: 10744089].
35. de A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947 [PMID: 10944126].
36. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-1347 [PMID: 10658525].
37. Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000; 11: 1477-1483 [PMID: 11142489].
38. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35: 1338-1342 [PMID: 10658524].
39. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery- Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237 [PMID: 14657227 DOI: 10.1200/JCO.2004.05.113].
40. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/JCO.2006.09.0928].
41. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487 [PMID: 15689586 DOI: 10.1056/NEJMra040958].
42. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019].
43. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691].
44. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling- Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4].
45. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930].
46. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620].
47. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasinska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860].
48. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007; 12: 913-923 [PMID: 17766650 DOI: 10.1634/theoncologist.12-8-913].
49. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175 [PMID: 7565971 DOI: 10.1056/NEJM199511023331802].
50. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-8174 [PMID: 9653159].
51. Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M, Yasumura S, Maki K, Aikawa S, Hayasaka K. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J Hum Genet 1999; 44: 22-25 [PMID: 9929972 DOI: 10.1007/s100380050100].
52. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10- hydroxycamPTothecin (SN-38). Mol Pharmacol 2002; 62: 608-617 [PMID: 12181437].
53. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D' Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S. The role of UGT1A1∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-3068 [PMID: 16809730 DOI: 10.1200/JCO.2005.05.5400].
54. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to oPTimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 2014; 32: 2328-2334 [PMID: 24958824 DOI: 10.1200/JCO.2014.55.2307].
55. Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Araki K, Ichikawa W, Miya T, Narabayashi M, Kawara K, Sugiyama M, Hirose T, Ando Y, Sasaki Y. Genetic testing for UGT1A1∗28 and ∗6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 2008; 19: 2089-2090 [PMID: 18953066 DOI: 10.1093/annonc/mdn645].
56. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25: 2594-2600 [PMID: 17577039 DOI: 10.1200/JCO.2006.10.2301].
57. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. matters. J Natl Cancer Inst 2007; 99: 1290-1295 [PMID: 17728214 DOI: 10.1093/jnci/djm115].
58. Ichikawa W, Araki K, Fujita K, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Kodama K, Sunakawa Y, Narabayashi M, Ando Y, Akiyama Y, Kawara K, Sasaki Y. Re: UGT1A1∗28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2008; 100: 224-225; author reply 225 [PMID: 18230796 DOI: 10.1093/jnci/djm302].
59. Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 2011; 105: 53-57 [PMID: 21654688 DOI: 10.1038/bjc.2011.206].
60. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 866-871 [PMID: 20038727 DOI: 10.1200/JCO.2009.23.6125].
61. Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther 2013; 94: 23-26 [PMID: 23778707 DOI: 10.1038/clPT.2013.12].
62. Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I. Life-threatening toxicities in a patient with UGT1A1∗6/∗28 and SLCO1B1∗15/∗15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 2009; 63: 1165-1169 [PMID: 18998132 DOI: 10.1007/s00280- 008-0864-x].
63. Xiang X, Jada SR, Li HH, Fan L, Tham LS, Wong CI, Lee SC, Lim R, Zhou QY, Goh BC, Tan EH, Chowbay B. Pharmacogenetics of SLCO1B1 gene and the impact of ∗1b and ∗15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 2006; 16: 683-691 [PMID: 16906022 DOI: 10.1097/01. fpc.0000230420.05221.71].
64. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS. Influence of the organic anion-transporting polypePTide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 2008; 59: 69-75 [PMID: 17766002 DOI: 10.1016/j.lungcan.2007.07.019].
65. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604-2614 [PMID: 19349540 DOI: 10.1200/JCO.2008.20.6300].
66. De Mattia E, Toffoli G, Polesel J, D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics 2013; 23: 549-557 [PMID: 24018773 DOI: 10.1097/FPC.0b013e328364b6cf].
67. Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer 2015; 112: 857-865 [PMID: 25611302 DOI: 10.1038/bjc.2015.5].
68. de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004; 10: 4068-4071 [PMID: 15217940 DOI: 10.1158/1078-0432.CCR-03-0591].
69. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B. Role of UGT1A1∗6, UGT1A1∗28 and ABCG2 c.421C& gt; A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007; 98: 1461-1467 [PMID: 17627617 DOI: 10.1111/j.1349-7006.2007.00541.x].
70. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009; 63: 115-120 [PMID: 18221820 DOI: 10.1016/j.lungcan.2007.12.003].
71. de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42-49 [PMID: 17185998 DOI: 10.1038/sj.clPT.6100019].
72. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-147 [PMID: 17534875 DOI: 10.1002/cncr.22760].
73. Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y. Association of ATP-binding cassette, subfamily C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 2008; 31: 2137-2142 [PMID: 18981587].
74. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60: 1189-1192 [PMID: 10728672].
75. Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008; 13: 412-431 [PMID: 18305428].
76. Kubo T, Kim SR, Sai K, Saito Y, Nakajima T, Matsumoto K, Saito H, Shirao K, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Ohno Y, Ozawa S, Sawada J. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos 2005; 33: 1482-1487 [PMID: 16033949 DOI: 10.1124/dmd.105.005587].
77. Kim SR, Sai K, Tanaka-Kagawa T, Jinno H, Ozawa S, Kaniwa N, Saito Y, Akasawa A, Matsumoto K, Saito H, Kamatani N, Shirao K, Yamamoto N, Yoshida T, Minami H, Ohtsu A, Saijo N, Sawada J. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos 2007; 35: 1865-1872 [PMID: 17640957 DOI: 10.1124/dmd.107.015339].
78. Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki- Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol 2010; 70: 222-233 [PMID: 20653675 DOI: 10.1111/j.1365-2125.2010.03695.x].
79. Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther 2014; 96: 340-348 [PMID: 24926778 DOI: 10.1038/clPT.2014.129].
80. Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: A review. Curr Clin Pharmacol 2010; 5: 209-217 [PMID: 20406168].
81. Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and nonelderly patients: why is toxicity increased in elderly patients? J Clin Oncol 2004; 22: 2901-2908 [PMID: 15254059 DOI: 10.1200/JCO.2004.10.163].
82. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, Tranchand B, Shapira I, Aapro M. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007; 25: 1832-1843 [PMID: 17488981 DOI: 10.1200/JCO.2007.10.6583].
83. Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic andpharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998; 35: 49-64 [PMID: 9673834 DOI: 10.21 65/00003088-199835010-00004].
84. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981; 6: 389-396 [PMID: 7333060].
85. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19: 359-389 [PMID: 2268986 DOI: 10.2165/00003088-199019050-00002].
86. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331-339 [PMID: 9091249 DOI: 10.1016/S0009-9236(97)90166-1].
87. Lichtman SM, Skirvin JA, Vemulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 2003; 46: 101-114 [PMID: 12711355].
88. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-795 [PMID: 10091755].
89. Sastre J, Puente J, García-Saenz JA, Díaz-Rubio E. Irinotecan in the treatment of elderly patients with advanced colorectal cancer. Crit Rev Oncol Hematol 2008; 68: 250-255 [PMID: 18722784 DOI: 10.1016/j.critrevonc.2008.05.008].
90. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825 [PMID: 21872750 DOI: 10.1016/S0140-6736(11)60814-3].
91. Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013; 10: 451-459 [PMID: 23856744 DOI: 10.1038/nrclinonc.2013.108].
92. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30: 1553-1561 [PMID: 22473167 DOI: 10.1200/JCO.2011.39.9436].
93. Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 2002; 20: 81-87 [PMID: 11773157].
94. Phelps MA, Sparreboom A. Irinotecan pharmacogenetics: A finished puzzle? J Clin Oncol 2014; 32: 2287-2289 [PMID: 24958823 DOI: 10.1200/JCO.2014.56.3387].
95. Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20: 4303-4312 [PMID: 12409328].
96. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14: 1783-1790 [PMID: 14630685].
97. Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, ComPTon LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res 2006; 12: 3782-3791 [PMID: 16778106 DOI: 10.1158/1078-0432.CCR-05-2152].
98. de Jong FA, Kitzen JJ, de Bruijn P, Verweij J, Loos WJ. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther 2006; 5: 1105-1110 [PMID: 16969123].
99. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, ComPTon LD, Miller LL, Baker DS, Pesheck CV, Lord RS. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28: 423-433 [PMID: 10725311].
100. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4: 2747-2754 [PMID: 9829738].
101. Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y. Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos 2011; 39: 161-164 [PMID: 20980446 DOI: 10.1124/dmd.110.035451].
102. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 2000; 6: 3451-3458 [PMID: 10999728].
103. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, Verweij J. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 2008; 84: 254-262 [PMID: 18288083 DOI: 10.1038/sj.clPT.6100513].
104. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78: 388-399 [PMID: 16198658 DOI: 10.1016/j.clPT.2005.07.005].
105. Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 2008; 84: 488-496 [PMID: 19238654].
106. Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67: 7-15 [PMID: 10668848 DOI: 10.1067/mcp.2000.103973].
107. Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, Arya V, Berglund EG, Atkinson AJ, Sugiyama Y, Pang KS, Reynolds KS, Abernethy DR, Zhang L, Lesko LJ, Huang SM. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52: 91S-108S [PMID: 22232759 DOI: 10.1177/009127001141552 8].
108. Li J, Wan Y, Na S, Liu X, Dong G, Yang Z, Yang J, Yue J. Sexdependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBPα, and RXRα. Biochem Pharmacol 2015; 93: 92-103 [PMID: 25451687 DOI: 10.1016/j.bcp.2014.10.010].
109. Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 2008; 62: 529-537 [PMID: 17992531 DOI: 10.1007/s00280-007-0634-1].
110. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010; 42: 209-224 [PMID: 19821798 DOI: 10.3109/03602530903209288].
111. Klein CE, GuPTa E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 2002; 72: 638-647 [PMID: 12496745 DOI: 10.1067/mcp.2002.129502].
112. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T, Minami H, Sasaki Y. Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001; 19: 61-67 [PMID: 11291833].
113. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-2465 [PMID: 19364970 DOI: 10.1200/JCO.2008.19.0314].
114. Sasaki T, Fujita K, Sunakawa Y, Ishida H, Yamashita K, Miwa K, Saji S, Kato Y, Sasaki Y. Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. Int J Clin Oncol 2013; 18: 735-742 [PMID: 22638624 DOI: 10.1007/s10147-012-0425-5].
115. van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25: 2719-2726 [PMID: 17563393 DOI: 10.1200/JCO.2006.09.6115].